Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Sanan Rasheed, MBBS
Advertisement
Articles by Sanan Rasheed, MBBS
Advertisement
Latest Updated Articles
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentPublished: August 14th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
2
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
3
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma
4
TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC
5
